Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Sliding Again Today

By Keith Speights – Oct 4, 2021 at 12:08PM

Key Points

  • Moderna stock fell last week on Merck's positive data for a COVID-19 pill developed with Ridgeback.
  • The downtrend continued this week.
  • This sell-off could be an overreaction, though.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to still be worried about Merck's COVID-19 pill.

What happened

Shares of Moderna (MRNA -0.70%) are sliding 5.9% lower as of 11:49 a.m. EDT on Monday. This drop appears to be a continuation of the sharp decline that began last week after Merck (MRK 0.36%) and Ridgeback Biotherapeutics announced positive results from a late-stage study of COVID-19 pill molnupiravir.

So what

Other vaccine stocks also are continuing to fall in response to Merck's good news. However, this appears to be an overreaction. The availability of a safe and effective oral therapy for COVID-19 isn't likely to cause the U.S. or other countries to change their focus on vaccinations.

A person with hands on hip looking at a screen showing coronavirus with a city in the background.

Image source: Getty Images.

In its second-quarter update in August, Moderna reported purchase agreements for its COVID-19 vaccine of roughly $12 billion for delivery in 2022. In addition, those agreements included options for another $8 billion.

Since then, the company has made another supply agreement with Canada to provide 20 million doses per year in 2022 and 2023. Canada also has options to buy 15 million more doses per year plus up to 35 million doses in 2024. Moderna recently inked a deal with Peru as well to supply 20 million doses next year.  

Merck's positive results probably won't change anything with Moderna's vaccine sales over the next couple of years. However, it's appropriate that investors are taking a hard look at the stock's valuation in light of the uncertainty related to ongoing COVID-19 vaccine sales after the pandemic ends.

Now what

The next big thing to watch with Moderna is the upcoming U.S. Food and Drug Administration and Centers for Disease Control & Prevention review of boosters for the company's COVID-19 vaccine. Data should also be released in the near future about the use of Moderna's vaccine in mix-and-match studies with other vaccines.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$174.16 (-0.70%) $-1.23
Merck & Co. Stock Quote
Merck & Co.
$108.84 (0.36%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.